Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12Head & Neck 9Gastrointestinal 8Genitourinary 7Dermatologic 7Gynecologic 6Lymphoid 3Sarcoma 2CNS 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Sarcoma 1Gastrointestinal Stromal Tumors 1

Interventions

Temozolomide 63Cyclophosphamide 55Radiotherapy 53Bevacizumab 50Doxorubicin 48Ifosfamide 33pazopanib 28fludarabine phosphate 28Etoposide 27Radiation 24Gemcitabine 24pembrolizumab 23Sirolimus 23Sunitinib 22Filgrastim 22Irinotecan 21Whole-Body Irradiation 20Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 20Imatinib Mesylate 20Vincristine 19Magnetic Resonance Spectroscopy 18Sorafenib 16Methotrexate 16Busulfan 16Melphalan 15Carboplatin 15Docetaxel 14Cyclosporine 14temsirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × epacadostat × Sarcoma × Clear all
NCT03414229 2026-04-23

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled 11 charts
Sarcoma

Sarcoma

NCT03291054 2024-06-11

Epacadostat and Pembrolizumab in Patients With GIST

Columbia University

Phase 2 Terminated
1 enrolled 1 chart
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡